GlobeNewswire Clinical StudiesOriginal article
Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS)
Phase 3brepocitinibPositive
AI Analysis
Summary
Priovant announced the first patient enrollment in BEACON+, a Phase 3 study of brepocitinib in cutaneous sarcoidosis, following positive Phase 2 results and FDA Breakthrough Therapy Designation.
Clinical Trial Data
Phase
3
Outcome Details
First patients enrolled in Phase 3 study (BEACON+)
Importance:6/10
Sentiment:
0.70
Phase 3cutaneous sarcoidosisBreakthrough Therapy DesignationbrepocitinibBEACON+
Related Companies
Read the original article
Published by GlobeNewswire Clinical Studies on August 6, 2026 11:00 AM